Amelocerebrohypohidrotic syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1946OMIM:226750G40.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Amelocerebrohypohidrotic syndrome, also known as Kohlschütter-Tönz syndrome (KTS), is a rare neurodegenerative disorder characterized by the combination of amelogenesis imperfecta (yellow-brown discoloration and abnormal enamel formation of the teeth), epilepsy, and intellectual disability. The condition was first described by Kohlschütter and colleagues in 1974. It primarily affects the central nervous system, teeth, and sweat glands (with reduced sweating or hypohidrosis being a variable feature). The syndrome typically presents in infancy or early childhood with seizures that may be difficult to control, progressive psychomotor regression or developmental delay, and characteristic dental enamel defects known as amelogenesis imperfecta, which gives the teeth a distinctly abnormal yellow-brown appearance. The condition is caused by mutations in the ROGDI gene (also referred to as leucine zipper-containing protein), located on chromosome 16p13.3. The ROGDI protein is believed to play a role in neuronal function, though its precise biological mechanism is not yet fully understood. The epilepsy associated with this syndrome can be severe and often refractory to standard antiepileptic medications. Affected individuals typically experience progressive cognitive decline and spasticity over time. There is currently no cure or disease-specific treatment for Kohlschütter-Tönz syndrome. Management is supportive and symptomatic, focusing on seizure control with antiepileptic drugs, dental care and restorative treatments for enamel defects, physical therapy, and developmental support. The prognosis varies but is generally guarded, with many patients experiencing significant neurological deterioration. Early diagnosis through clinical recognition of the triad of epilepsy, intellectual disability, and amelogenesis imperfecta, combined with genetic testing for ROGDI mutations, is important for appropriate management and genetic counseling.

Also known as:

Clinical phenotype terms— hover any for plain English:

Yellow-brown discoloration of the teethHP:0006286Abnormality of dental colorHP:0011073Amelogenesis imperfectaHP:0000705
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Amelocerebrohypohidrotic syndrome.

View clinical trials →

No actively recruiting trials found for Amelocerebrohypohidrotic syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Amelocerebrohypohidrotic syndrome community →

No specialists are currently listed for Amelocerebrohypohidrotic syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Amelocerebrohypohidrotic syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Amelocerebrohypohidrotic syndromeForum →

No community posts yet. Be the first to share your experience with Amelocerebrohypohidrotic syndrome.

Start the conversation →

Latest news about Amelocerebrohypohidrotic syndrome

No recent news articles for Amelocerebrohypohidrotic syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Amelocerebrohypohidrotic syndrome

What is Amelocerebrohypohidrotic syndrome?

Amelocerebrohypohidrotic syndrome, also known as Kohlschütter-Tönz syndrome (KTS), is a rare neurodegenerative disorder characterized by the combination of amelogenesis imperfecta (yellow-brown discoloration and abnormal enamel formation of the teeth), epilepsy, and intellectual disability. The condition was first described by Kohlschütter and colleagues in 1974. It primarily affects the central nervous system, teeth, and sweat glands (with reduced sweating or hypohidrosis being a variable feature). The syndrome typically presents in infancy or early childhood with seizures that may be difficu

How is Amelocerebrohypohidrotic syndrome inherited?

Amelocerebrohypohidrotic syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Amelocerebrohypohidrotic syndrome typically begin?

Typical onset of Amelocerebrohypohidrotic syndrome is infantile. Age of onset can vary across affected individuals.